Curis (CRIS) Stock Forecast & Price Target

Curis is supported by increasingly compelling emavertib PCNSL data, where the BTKi-naïve cohort reached 100% ORR in five of five evaluable patients and the broader BTKi-experienced group improved to 33% in 30 evaluable patients, with management saying the dataset could support accelerated approval filing in the U.S. and a Conditional Marketing Authorization submission in Europe. The investment case is also broadened by the TakeAim CLL study, which dosed its first five patients on July 30, 2026 across 11 active sites and raised year-end 2026 guidance to five to ten patients, offering another potential proof point for dual NF-κB blockade in a frontline BTKi setting. Financially, Curis ended 2Q26 with $5.07 million in cash, added about $4.8 million from a subsequent public offering, and currently has funding only into 4Q26, making clinical execution and financing the key swing factors.

Curis is facing a weak fundamental setup because its lead PCNSL data showed no meaningful improvement in the key BTKi-experienced registrational cohort, with all-patients ORR essentially flat at 26% versus 27% previously even as enrollment rose to 39 patients. The apparent 33% evaluable response rate is less persuasive because it excludes 9 patients who did not complete a 28-day cycle, which can overstate efficacy versus the full enrolled population, while the company still needs 45-60 patients and must fund a randomized confirmatory study before filing. In CLL, the program remains very early and risky, with only 10 consented patients, raised year-end guidance of 5-10, and a low 10% probability of success, leaving the investment case dependent on fragile clinical data rather than durable financial or commercial strength.